ArticleHuman vaccines & immunotherapeutics2025
The safety of co-administration of recombinant zoster vaccine (Shingrix) and influenza vaccines in the elderly in VAERS during 2018-2024.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Integrating non-neonatal tetanus vaccination into an emergency department rabies PEP clinic: Real-world workload, documentation gaps, and VAERS-informed observation priorities.Human vaccines & immunotherapeutics · 2026Article
- Structured Pharmacist-Led Vaccine Recommendation and Coadministration in Community Pharmacies: Real-World Evidence from Poland.Vaccines · 2026Article
- Mitigating Vaccine Disparities Through Faith-Based Intervention: A Pre-Post Analysis of Recombinant Zoster Vaccine Knowledge and Acceptance in Socially Vulnerable Racial and Ethnic Minoritized Communities.Infectious diseases and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This post-marketing safety study evaluated the co-administration of recombinant zoster vaccine (RZV, Shingrix) and influenza vaccines (HD-IIV/aIIV/RIV) in adults aged ≥ 65 years using U.S. VAERS data (2018-2024). Among 791 adverse event (AE) reports analyzed via empirical Bayesian data mining and clinical review, 55 (6.9%) were serious, with non-serious AEs dominated by injection site reactions (65%), pyrexia (15.2%), and chills (13.4%). Serious AEs included asthenia (8.1%), pyrexia (8.1%), and Guillain-Barré syndrome (GBS, 6.4%); clinical review confirmed 7 Brighton-criteria GBS cases and one Bell's palsy. Data mining detected no new safety signals, and comparative analysis revealed that co-administration safety aligned with clinical trial profiles and monotherapy (influenza/RZV alone), showing no elevated risks. These findings support co-administration safety in older adults, advocating for community pharmacy-based delivery to optimize coverage. Limitations include VAERS' passive surveillance nature (underreporting, lack of denominator data), necessitating cautious interpretation and ongoing monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.